<sec><b>Objectives</b><p>Echovirus 30 is a major cause of meningitis in children and adults. The aim of this study was to investigate whether the antifungal drug itraconazole could exhibit antiviral activity against echovirus 30.</p></sec><sec><b>Methods</b><p>The cytopathic effect and viral RNA levels were assessed in RD cells as indicators of viral replication. The effects of itraconazole were compared to those of two known antiviral drugs, rupintrivir and pleconaril. The time course and time-of-addition assays were used to approximate the time at which itraconazole exerts its activity in the viral cycle.</p></sec><sec><b>Results</b><p>Itraconazole and rupintrivir demonstrated the greatest potency against echovirus 30, demonstrating concentration-dependent activity, whereas pleconaril showed no antiviral activity. Itraconazole did not directly inactivate echovirus 30 particles or impede viral uptake into RD cells, but did affect the initial stages of echovirus 30 infection through interference with viral replication.</p></sec><sec><b>Conclusion</b><p>Itraconazole can be considered a lead candidate for the development of antiviral drugs against echovirus 30 that may be used during the early stages of echovirus 30 replication.</p></sec>
Citations
Citations to this article as recorded by
Toward Personalized Medicine: The Effect of Treatment of Chronic Enterovirus Diarrhea in an Immunocompromised Patient and the Correlation With In Vitro Models Giulia Moreni, Carlemi Calitz, Gerrit Koen, Hetty van Eijk, Nina Johannesson, Jamy De Ruijter, Kimberley S M Benschop, Jeroen Cremer, Dasja Pajkrt, Adithya Sridhar, Edgar J Peters, Katja C Wolthers Open Forum Infectious Diseases.2025;[Epub] CrossRef
Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances Chiara Tammaro, Michela Guida, Federico Appetecchia, Mariangela Biava, Sara Consalvi, Giovanna Poce Pharmaceuticals.2023; 16(2): 203. CrossRef
Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery Leena Abdulaziz, Esraa Elhadi, Ejlal A Abdallah, Fadlalbaseer A Alnoor, Bashir A Yousef Journal of Experimental Pharmacology.2022; Volume 14: 97. CrossRef
Identification of novel Ebola virus inhibitors using biologically contained virus Bert Vanmechelen, Joren Stroobants, Winston Chiu, Joost Schepers, Arnaud Marchand, Patrick Chaltin, Kurt Vermeire, Piet Maes Antiviral Research.2022; 200: 105294. CrossRef
The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication Lucca Policastro, Isabela Dolci, Andre Godoy, José Silva Júnior, Uriel Ruiz, Igor Santos, Ana Jardim, Kirandeep Samby, Jeremy Burrows, Timothy Wells, Laura Gil, Glaucius Oliva, Rafaela Fernandes Viruses.2022; 14(7): 1351. CrossRef
Itraconazole and Posaconazole from Antifungal to Antiviral Drugs Falah Hasan Obayes AL-Khikani Biomedical and Biotechnology Research Journal (BBR.2022; 6(2): 164. CrossRef
Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle Eric Rhoden, Terry Fei Fan Ng, Ray Campagnoli, W. Allan Nix, Jennifer Konopka-Anstadt, Rangaraj Selvarangan, Laurence Briesach, M. Steven Oberste, William C. Weldon Antimicrobial Agents and Chemotherapy.2020;[Epub] CrossRef
Potential antiviral properties of antifungal drugs FalahH.O Al-Khikani, HudaA.S Almosawey, YounusJ Abdullah, AtyafA Al-Asadi, RaghdahM Hameed, NoorF Hasan, MohanadK.M Al-Ibraheemi Journal of the Egyptian Women's Dermatologic Socie.2020; 17(3): 185. CrossRef
First
Prev
